At-home sample collection is an effective strategy for diagnosis and management of symptomatic and asymptomatic SARS-CoV-2 carriers View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2022-05-09

AUTHORS

Devon P. Humphreys, Kathleen M. Gavin, Kaylan M. Olds, Marc P. Bonaca, Timothy A. Bauer

ABSTRACT

BackgroundDiagnostic testing accessibility and asymptomatic transmission of SARS-CoV-2 present major challenges for curbing and preventing community prevalence of COVID-19. At-home sample collection for molecular testing provides a convenient and effective solution for disease containment and prevention.MethodsThis is a retrospective, cross-sectional, case-control study. Our primary aim was to determine the prevalence and relative risk of SARS-CoV-2 among asymptomatic versus symptomatic individuals using at-home sample collection kits for diagnosis. Participants included adults from across the United States who completed a COVID-19 Home Collection kit between May 2020 and September 2021. Main measurements included self-reported symptoms and at-home self-collected anterior nasal swab RT-PCR test results for SARS-CoV-2.ResultsData from 282,831 individuals were included in this analysis. The overall SARS-CoV-2 prevalence of at-home test takers was low compared to national averages during this period (3.28% vs. 7.68%). Those reporting no symptoms were at lower risk of positive test results compared to those with symptoms (risk ratio: 0.080, 95% CI, 0.078–0.082). However, of all positive SARS-CoV-2 tests, 48.75% were from individuals reporting no symptoms at the time of testing.ConclusionsWe conclude that at-home sample collection is a viable option and potentially important strategy for improving access to testing, detecting asymptomatic cases, and curbing preventable transmission of COVID-19. More... »

PAGES

443

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12879-022-07377-4

DOI

http://dx.doi.org/10.1186/s12879-022-07377-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1147723550

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/35534836


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "COVID-19", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Case-Control Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cross-Sectional Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "SARS-CoV-2", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Everly Health, Inc, 823 Congress Ave., Suite 1200, 78701, Austin, TX, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Everly Health, Inc, 823 Congress Ave., Suite 1200, 78701, Austin, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Humphreys", 
        "givenName": "Devon P.", 
        "id": "sg:person.0604457715.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0604457715.92"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Colorado Anschutz Medical Campus, Aurora, CO, USA", 
          "id": "http://www.grid.ac/institutes/grid.430503.1", 
          "name": [
            "Everly Health, Inc, 823 Congress Ave., Suite 1200, 78701, Austin, TX, USA", 
            "University of Colorado Anschutz Medical Campus, Aurora, CO, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gavin", 
        "givenName": "Kathleen M.", 
        "id": "sg:person.01114517607.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01114517607.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Everly Health, Inc, 823 Congress Ave., Suite 1200, 78701, Austin, TX, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Everly Health, Inc, 823 Congress Ave., Suite 1200, 78701, Austin, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Olds", 
        "givenName": "Kaylan M.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "CPC Clinical Research, Aurora, CO, USA", 
          "id": "http://www.grid.ac/institutes/grid.266190.a", 
          "name": [
            "University of Colorado Anschutz Medical Campus, Aurora, CO, USA", 
            "CPC Clinical Research, Aurora, CO, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bonaca", 
        "givenName": "Marc P.", 
        "id": "sg:person.01245524245.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01245524245.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Colorado Anschutz Medical Campus, Aurora, CO, USA", 
          "id": "http://www.grid.ac/institutes/grid.430503.1", 
          "name": [
            "Everly Health, Inc, 823 Congress Ave., Suite 1200, 78701, Austin, TX, USA", 
            "University of Colorado Anschutz Medical Campus, Aurora, CO, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bauer", 
        "givenName": "Timothy A.", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/s41579-020-00459-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1131440039", 
          "https://doi.org/10.1038/s41579-020-00459-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13027-021-00388-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1139062341", 
          "https://doi.org/10.1186/s13027-021-00388-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12916-021-01982-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1137491037", 
          "https://doi.org/10.1186/s12916-021-01982-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41591-020-0965-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1128556366", 
          "https://doi.org/10.1038/s41591-020-0965-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12985-021-01597-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1138795159", 
          "https://doi.org/10.1186/s12985-021-01597-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12985-021-01533-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1136554695", 
          "https://doi.org/10.1186/s12985-021-01533-z"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2022-05-09", 
    "datePublishedReg": "2022-05-09", 
    "description": "BackgroundDiagnostic testing accessibility and asymptomatic transmission of SARS-CoV-2 present major challenges for curbing and preventing community prevalence of COVID-19. At-home sample collection for molecular testing provides a convenient and effective solution for disease containment and prevention.MethodsThis is a retrospective, cross-sectional, case-control study. Our primary aim was to determine the prevalence and relative risk of SARS-CoV-2 among asymptomatic versus symptomatic individuals using at-home sample collection kits for diagnosis. Participants included adults from across the United States who completed a COVID-19 Home Collection kit between May 2020 and September 2021. Main measurements included self-reported symptoms and at-home self-collected anterior nasal swab RT-PCR test results for SARS-CoV-2.ResultsData from 282,831 individuals were included in this analysis. The overall SARS-CoV-2 prevalence of at-home test takers was low compared to national averages during this period (3.28% vs. 7.68%). Those reporting no symptoms were at lower risk of positive test results compared to those with symptoms (risk ratio: 0.080, 95% CI, 0.078\u20130.082). However, of all positive SARS-CoV-2 tests, 48.75% were from individuals reporting no symptoms at the time of testing.ConclusionsWe conclude that at-home sample collection is a viable option and potentially important strategy for improving access to testing, detecting asymptomatic cases, and curbing preventable transmission of COVID-19.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12879-022-07377-4", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024946", 
        "issn": [
          "1471-2334"
        ], 
        "name": "BMC Infectious Diseases", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "22"
      }
    ], 
    "keywords": [
      "home sample collection", 
      "asymptomatic SARS-CoV-2 carriers", 
      "positive SARS-CoV-2 test", 
      "SARS-CoV-2 carriers", 
      "RT-PCR test results", 
      "SARS-CoV-2 test", 
      "SARS-CoV-2 prevalence", 
      "home collection kit", 
      "case-control study", 
      "collection kit", 
      "positive test results", 
      "COVID-19", 
      "SARS-CoV-2", 
      "self-reported symptoms", 
      "preventable transmission", 
      "asymptomatic cases", 
      "community prevalence", 
      "time of testing", 
      "relative risk", 
      "sample collection", 
      "symptomatic individuals", 
      "asymptomatic transmission", 
      "lower risk", 
      "molecular testing", 
      "symptoms", 
      "disease containment", 
      "prevalence", 
      "primary aim", 
      "diagnosis", 
      "national average", 
      "risk", 
      "main measurements", 
      "viable option", 
      "individuals", 
      "kit", 
      "MethodsThis", 
      "effective strategy", 
      "important strategy", 
      "testing", 
      "prevention", 
      "adults", 
      "United States", 
      "ConclusionsWe", 
      "test results", 
      "present major challenges", 
      "participants", 
      "transmission", 
      "options", 
      "aim", 
      "management", 
      "period", 
      "strategies", 
      "cases", 
      "study", 
      "major challenge", 
      "test", 
      "collection", 
      "results", 
      "average", 
      "access", 
      "carriers", 
      "containment", 
      "time", 
      "analysis", 
      "challenges", 
      "accessibility", 
      "takers", 
      "measurements", 
      "state", 
      "test takers", 
      "effective solution", 
      "solution"
    ], 
    "name": "At-home sample collection is an effective strategy for diagnosis and management of symptomatic and asymptomatic SARS-CoV-2 carriers", 
    "pagination": "443", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1147723550"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12879-022-07377-4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35534836"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12879-022-07377-4", 
      "https://app.dimensions.ai/details/publication/pub.1147723550"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-06-01T22:25", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220601/entities/gbq_results/article/article_935.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12879-022-07377-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12879-022-07377-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12879-022-07377-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12879-022-07377-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12879-022-07377-4'


 

This table displays all metadata directly associated to this object as RDF triples.

219 TRIPLES      22 PREDICATES      111 URIs      97 LITERALS      14 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12879-022-07377-4 schema:about N1f9e2b36b2e74a8b972d7812882635b9
2 N5e02f703c6e44fdb889aaf23df274318
3 N64a282736cd6404597358212859e1768
4 N9b5064dae90540cd941f0321a1fd3048
5 Na65d0ef1342649c08eeba96af6a7ba8e
6 Nc1361572930d4e1bb97ece5e81edb229
7 Nf6fd54896adb418aa76c4d787ffeeeb0
8 anzsrc-for:11
9 anzsrc-for:1117
10 schema:author N2ecea45d64f8402ba657be614944702d
11 schema:citation sg:pub.10.1038/s41579-020-00459-7
12 sg:pub.10.1038/s41591-020-0965-6
13 sg:pub.10.1186/s12916-021-01982-x
14 sg:pub.10.1186/s12985-021-01533-z
15 sg:pub.10.1186/s12985-021-01597-x
16 sg:pub.10.1186/s13027-021-00388-x
17 schema:datePublished 2022-05-09
18 schema:datePublishedReg 2022-05-09
19 schema:description BackgroundDiagnostic testing accessibility and asymptomatic transmission of SARS-CoV-2 present major challenges for curbing and preventing community prevalence of COVID-19. At-home sample collection for molecular testing provides a convenient and effective solution for disease containment and prevention.MethodsThis is a retrospective, cross-sectional, case-control study. Our primary aim was to determine the prevalence and relative risk of SARS-CoV-2 among asymptomatic versus symptomatic individuals using at-home sample collection kits for diagnosis. Participants included adults from across the United States who completed a COVID-19 Home Collection kit between May 2020 and September 2021. Main measurements included self-reported symptoms and at-home self-collected anterior nasal swab RT-PCR test results for SARS-CoV-2.ResultsData from 282,831 individuals were included in this analysis. The overall SARS-CoV-2 prevalence of at-home test takers was low compared to national averages during this period (3.28% vs. 7.68%). Those reporting no symptoms were at lower risk of positive test results compared to those with symptoms (risk ratio: 0.080, 95% CI, 0.078–0.082). However, of all positive SARS-CoV-2 tests, 48.75% were from individuals reporting no symptoms at the time of testing.ConclusionsWe conclude that at-home sample collection is a viable option and potentially important strategy for improving access to testing, detecting asymptomatic cases, and curbing preventable transmission of COVID-19.
20 schema:genre article
21 schema:inLanguage en
22 schema:isAccessibleForFree true
23 schema:isPartOf N8a6bc04d5acf4d8491b645a14f890e9a
24 Nbb5a424261074709bdeab58dbb305536
25 sg:journal.1024946
26 schema:keywords COVID-19
27 ConclusionsWe
28 MethodsThis
29 RT-PCR test results
30 SARS-CoV-2
31 SARS-CoV-2 carriers
32 SARS-CoV-2 prevalence
33 SARS-CoV-2 test
34 United States
35 access
36 accessibility
37 adults
38 aim
39 analysis
40 asymptomatic SARS-CoV-2 carriers
41 asymptomatic cases
42 asymptomatic transmission
43 average
44 carriers
45 case-control study
46 cases
47 challenges
48 collection
49 collection kit
50 community prevalence
51 containment
52 diagnosis
53 disease containment
54 effective solution
55 effective strategy
56 home collection kit
57 home sample collection
58 important strategy
59 individuals
60 kit
61 lower risk
62 main measurements
63 major challenge
64 management
65 measurements
66 molecular testing
67 national average
68 options
69 participants
70 period
71 positive SARS-CoV-2 test
72 positive test results
73 present major challenges
74 prevalence
75 preventable transmission
76 prevention
77 primary aim
78 relative risk
79 results
80 risk
81 sample collection
82 self-reported symptoms
83 solution
84 state
85 strategies
86 study
87 symptomatic individuals
88 symptoms
89 takers
90 test
91 test results
92 test takers
93 testing
94 time
95 time of testing
96 transmission
97 viable option
98 schema:name At-home sample collection is an effective strategy for diagnosis and management of symptomatic and asymptomatic SARS-CoV-2 carriers
99 schema:pagination 443
100 schema:productId N1ffe1f79e4444e9ca1346dda71727c41
101 N20dca7c956cb486e84c4f0341f70e397
102 N8df9e74945df42d59350b3edebebc788
103 schema:sameAs https://app.dimensions.ai/details/publication/pub.1147723550
104 https://doi.org/10.1186/s12879-022-07377-4
105 schema:sdDatePublished 2022-06-01T22:25
106 schema:sdLicense https://scigraph.springernature.com/explorer/license/
107 schema:sdPublisher Nf6a7e066941d47b3b3082493544200d6
108 schema:url https://doi.org/10.1186/s12879-022-07377-4
109 sgo:license sg:explorer/license/
110 sgo:sdDataset articles
111 rdf:type schema:ScholarlyArticle
112 N1f9e2b36b2e74a8b972d7812882635b9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Adult
114 rdf:type schema:DefinedTerm
115 N1ffe1f79e4444e9ca1346dda71727c41 schema:name doi
116 schema:value 10.1186/s12879-022-07377-4
117 rdf:type schema:PropertyValue
118 N20dca7c956cb486e84c4f0341f70e397 schema:name pubmed_id
119 schema:value 35534836
120 rdf:type schema:PropertyValue
121 N2e2f944783f4486e8b416b34a005cd08 schema:affiliation grid-institutes:grid.430503.1
122 schema:familyName Bauer
123 schema:givenName Timothy A.
124 rdf:type schema:Person
125 N2ecea45d64f8402ba657be614944702d rdf:first sg:person.0604457715.92
126 rdf:rest N871bed2abb3e470a8cbe8579aedff6d6
127 N3ddd062ed6044ad1824970784dad733f rdf:first N2e2f944783f4486e8b416b34a005cd08
128 rdf:rest rdf:nil
129 N5e02f703c6e44fdb889aaf23df274318 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Retrospective Studies
131 rdf:type schema:DefinedTerm
132 N64a282736cd6404597358212859e1768 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Case-Control Studies
134 rdf:type schema:DefinedTerm
135 N869e234929ca405c9d94feff3bcc1733 rdf:first Nf8b35d63dd6d415fa321b10c51215e0e
136 rdf:rest Nf4f47a19f533451f977ebc51d032fa06
137 N871bed2abb3e470a8cbe8579aedff6d6 rdf:first sg:person.01114517607.65
138 rdf:rest N869e234929ca405c9d94feff3bcc1733
139 N8a6bc04d5acf4d8491b645a14f890e9a schema:volumeNumber 22
140 rdf:type schema:PublicationVolume
141 N8df9e74945df42d59350b3edebebc788 schema:name dimensions_id
142 schema:value pub.1147723550
143 rdf:type schema:PropertyValue
144 N9b5064dae90540cd941f0321a1fd3048 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name COVID-19
146 rdf:type schema:DefinedTerm
147 Na65d0ef1342649c08eeba96af6a7ba8e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Humans
149 rdf:type schema:DefinedTerm
150 Nbb5a424261074709bdeab58dbb305536 schema:issueNumber 1
151 rdf:type schema:PublicationIssue
152 Nc1361572930d4e1bb97ece5e81edb229 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Cross-Sectional Studies
154 rdf:type schema:DefinedTerm
155 Nf4f47a19f533451f977ebc51d032fa06 rdf:first sg:person.01245524245.51
156 rdf:rest N3ddd062ed6044ad1824970784dad733f
157 Nf6a7e066941d47b3b3082493544200d6 schema:name Springer Nature - SN SciGraph project
158 rdf:type schema:Organization
159 Nf6fd54896adb418aa76c4d787ffeeeb0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name SARS-CoV-2
161 rdf:type schema:DefinedTerm
162 Nf8b35d63dd6d415fa321b10c51215e0e schema:affiliation grid-institutes:None
163 schema:familyName Olds
164 schema:givenName Kaylan M.
165 rdf:type schema:Person
166 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
167 schema:name Medical and Health Sciences
168 rdf:type schema:DefinedTerm
169 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
170 schema:name Public Health and Health Services
171 rdf:type schema:DefinedTerm
172 sg:journal.1024946 schema:issn 1471-2334
173 schema:name BMC Infectious Diseases
174 schema:publisher Springer Nature
175 rdf:type schema:Periodical
176 sg:person.01114517607.65 schema:affiliation grid-institutes:grid.430503.1
177 schema:familyName Gavin
178 schema:givenName Kathleen M.
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01114517607.65
180 rdf:type schema:Person
181 sg:person.01245524245.51 schema:affiliation grid-institutes:grid.266190.a
182 schema:familyName Bonaca
183 schema:givenName Marc P.
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01245524245.51
185 rdf:type schema:Person
186 sg:person.0604457715.92 schema:affiliation grid-institutes:None
187 schema:familyName Humphreys
188 schema:givenName Devon P.
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0604457715.92
190 rdf:type schema:Person
191 sg:pub.10.1038/s41579-020-00459-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1131440039
192 https://doi.org/10.1038/s41579-020-00459-7
193 rdf:type schema:CreativeWork
194 sg:pub.10.1038/s41591-020-0965-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1128556366
195 https://doi.org/10.1038/s41591-020-0965-6
196 rdf:type schema:CreativeWork
197 sg:pub.10.1186/s12916-021-01982-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1137491037
198 https://doi.org/10.1186/s12916-021-01982-x
199 rdf:type schema:CreativeWork
200 sg:pub.10.1186/s12985-021-01533-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1136554695
201 https://doi.org/10.1186/s12985-021-01533-z
202 rdf:type schema:CreativeWork
203 sg:pub.10.1186/s12985-021-01597-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1138795159
204 https://doi.org/10.1186/s12985-021-01597-x
205 rdf:type schema:CreativeWork
206 sg:pub.10.1186/s13027-021-00388-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1139062341
207 https://doi.org/10.1186/s13027-021-00388-x
208 rdf:type schema:CreativeWork
209 grid-institutes:None schema:alternateName Everly Health, Inc, 823 Congress Ave., Suite 1200, 78701, Austin, TX, USA
210 schema:name Everly Health, Inc, 823 Congress Ave., Suite 1200, 78701, Austin, TX, USA
211 rdf:type schema:Organization
212 grid-institutes:grid.266190.a schema:alternateName CPC Clinical Research, Aurora, CO, USA
213 schema:name CPC Clinical Research, Aurora, CO, USA
214 University of Colorado Anschutz Medical Campus, Aurora, CO, USA
215 rdf:type schema:Organization
216 grid-institutes:grid.430503.1 schema:alternateName University of Colorado Anschutz Medical Campus, Aurora, CO, USA
217 schema:name Everly Health, Inc, 823 Congress Ave., Suite 1200, 78701, Austin, TX, USA
218 University of Colorado Anschutz Medical Campus, Aurora, CO, USA
219 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...